Congenital Myasthenic Syndromes in 2012
Overview
Authors
Affiliations
Congenital myasthenic syndromes (CMS) represent a heterogeneous group of disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Clinical, electrophysiologic, and morphologic studies have paved the way for detecting CMS-related mutations in proteins residing in the nerve terminal, the synaptic basal lamina, or in the postsynaptic region of the motor endplate. The disease proteins identified to date include the acetylcholine receptor, acetylcholinesterase, choline acetyltransferase, rapsyn, and Na(v)1.4, muscle-specific kinase, agrin, β2-laminin, downstream of tyrosine kinase 7, and glutamine-fructose-6-phosphate transaminase 1. Analysis of electrophysiologic and biochemical properties of mutant proteins expressed in heterologous systems have contributed crucially to defining the molecular consequences of the observed mutations and have resulted in improved therapy of most CMS.
Mendpara V, Bethanabotla S, Yadav M, Kanisetti V, Singh G, Das A Cureus. 2023; 15(5):e38842.
PMID: 37303354 PMC: 10256249. DOI: 10.7759/cureus.38842.
The role of Rapsyn in neuromuscular junction and congenital myasthenic syndrome.
Liao X, Wang Y, Lai X, Wang S Biomol Biomed. 2023; 23(5):772-784.
PMID: 36815443 PMC: 10494853. DOI: 10.17305/bb.2022.8641.
Gomez-Garcia De la Banda M, Simental-Aldaba E, Fahmy N, Sternberg D, Blondy P, Quijano-Roy S Front Neurol. 2022; 13:909715.
PMID: 35720108 PMC: 9201482. DOI: 10.3389/fneur.2022.909715.
Alsallum M, Alshareef A, Abuzinadah A, Bamaga A, Dallol A Heliyon. 2021; 7(5):e06869.
PMID: 34027146 PMC: 8120944. DOI: 10.1016/j.heliyon.2021.e06869.
Ohkawara B, Shen X, Selcen D, Nazim M, Bril V, Tarnopolsky M JCI Insight. 2020; 5(7).
PMID: 32271162 PMC: 7205260. DOI: 10.1172/jci.insight.132023.